Immuno-Oncology Drugs Market is expected to witness a robust CAGR of 14.9% over the forecast period 2017 – 2025
To know the latest trends and insights prevalent in the global immuno-oncology drugs market, click the link below: https://www.coherentmarketinsights.com/market-insight/immuno-oncology-drugs-market-1271
Manufacturers are focusing on upgrading the available immune-oncology drugs as well as developing new immune-oncology drugs for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In August 2017, Novartis received approval for CAR-T therapy named Kymriah for children and young adult with B- cell lymphoblastic lymphoma. Gilead Life Science completed the acquisition of Kite pharma Ltd. in October 2017, and Gilead’s CAR-T therapy Yescarta received the U.S. Food & Drug Administration (FDA) approval in October 2017 to treat non-Hodgkin lymphoma. Celgene Corporation, in January 2018, announced acquisition of Juno Therapeutics, Inc. Through this acquisition, Celgene Corporation will gain access to novel CAR-T therapy, which is in pipeline of Juno Therapeutics. Furthermore, Amgen, Inc. received FDA approval, for Imlygic in 2017, which is an oncolytic virus to treat melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received FDA approval for the treatment of metastatic merkel cell carcinoma.
Browse 25 Market Data Tables and 38 Figures spread through 171 Pages and in-depth TOC on Global Immuno-Oncology Drugs Market By Drug Type,( Immune Checkpoint Inhibitors (CTL-4 Checkpoint Inhibitor, and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies (Naked, Conjugated, and Bispecific), Cytokine-Based Immunotherapy (Intron A and Proleukin), Cancer Vaccines (Preventive Vaccines and Treatment Vaccines), and CAR-T Cell Therapy (Kymriah and Yescarta)), By Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025
Research and development by leading as well as small and mid-sized players in immuno-oncology drugs market is expected to support growth of the global immuno-oncology drugs market. In January 2018, Feldan Therapeutics and Green Cross LabCell Collaborated to develop Natural Killer Cell-based Immunotherapies. In January 2018, OBI Pharma initiated Phase 1 Trial of immunotherapy candidate OBI-888 in advanced solid tumor patients. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications. In January 2018, the U.S. Food & Drug Administration granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer. Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials in December 2017. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.
Ask for detailed Sample of the Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271
*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it
Key Takeaways of the Global Immuno-Oncology Drugs Market:
The global immuno-oncology drugs market is expected to exhibit a CAGR of 14.9% over the forecast period. This is attributed to presence of number of leading manufacturers who are focusing on bringing out innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc.
Biopharmaceutical companies are developing a robust pipeline of immune-oncology therapies due to increasing demand for the same. The U.S. Food & Drug Administration has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
Immuno-oncology combination therapies are expected to change the market scenario over the forecast period, owing to positive results in the clinical trials
Research partnerships and collaborations to develop new drugs by various market players is supporting the growth of the market. as competitors would strive to gain competitive edge
Major players operating in the global immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immuno-Oncology Drugs Market is expected to witness a robust CAGR of 14.9% over the forecast period 2017 – 2025 here
News-ID: 984709 • Views: 207
More Releases from CMI - Market Research Reports
Bone Replacement Products Market– Effective Solution for Bone Problems
The innovative replacement systems are designed to provide patients with a joint preservation ultimatum, preserving the healthy parts of the knee, thus helping to maintain natural knee function. For instance, in 2014, Cayenne Medical launched the Mirror Partial Knee System, the only knee replacement system that uses the patient’s natural knee motion during the surgical procedure. This unique technology balances the knee throughout the entire range of motion. The
Multiplexed Diagnostic Market Driven By Innovation and Development of Technology
Mercodia has launched the AKURIO Islet Hormone multiplex assay with the collaboration of Quansys Bioscience in October 2017. This assay is designed to assess four different hormones in pancreatic study, which include glucagon, insulin, C-peptide, and proinsulin. AKURIO Islet Hormone multiplex assay provides high data accuracy with reliable speed. Moreover, Bruker has received CE-IVD marking for its Fungiplex Candida diagnostic assay in October 2017. Fungiplex Candida is based on real-time
U.S. Influenza Vaccines Market– Prevention of Virus through Vaccination Aids i …
The government agencies in the U.S. are focusing on collaborations in order to increase the supply of influenza vaccines. For instance, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza
Radiology Information System (RIS) Market: Market Competitive Situation and Tren …
North America is projected to witness high share in the radiology information system market, owing to the well-established healthcare infrastructure and early adoption of the advancement in the medical and healthcare industry in the U.S. Furthermore, Asia Pacific region is emerging region in radiology information system market, owing to the increasing investments on healthcare facilities and increasing demand for diagnosis and treatment of chronic disease. For instance, according to the
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and